Assessment of early paraprotein response to vincristine-doxorubicin- dexamethasone chemotherapy may help guide therapy in multiple myeloma

David Ross, L. B. To, Noemi Horvath

Research output: Contribution to journalReview articlepeer-review

8 Citations (Scopus)


Vincristine, doxorubicin and dexamethasone (VAD) are commonly used as the initial chemotherapy in myeloma patients prior to high-dose therapy and autologous stem cell transplantation. We reviewed monoclonal protein responses and survival of 62 patients treated in this way. Among patients with IgG paraprotein, achievement of at least 50% reduction in paraprotein after the first cycle of VAD correlated with significantly better event-free survival at 3 years, compared with those having less than 50% response. We postulate that early paraprotein response may be used to identify high risk patients.

Original languageEnglish
Pages (from-to)576-578
Number of pages3
JournalInternal Medicine Journal
Issue number9-10
Publication statusPublished or Issued - 1 Sep 2004
Externally publishedYes


  • Autologous transplantation
  • Multiple myeloma
  • Paraprotein
  • Prognostic factors

ASJC Scopus subject areas

  • Internal Medicine

Cite this